Teva Q2 2026: $4.1B Revenue, $1B+ Brand Growth & 2026 Outlook BoostTeva’s Q2 2026 earnings show a robust rebound in branded drugs, lifting 2026 outlook and sparking a share surge amid NYSE listing buzz.TEVA PHARMACEUTICAL Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 31/07/2026, 16:49 2 minutes to read
